MARKET

EIDX

EIDX

Eidos Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.39
-0.18
-0.32%
After Hours: 55.39 0 0.00% 16:30 01/17 EST
OPEN
56.06
PREV CLOSE
55.57
HIGH
56.06
LOW
55.02
VOLUME
43.65K
TURNOVER
--
52 WEEK HIGH
66.56
52 WEEK LOW
11.15
MARKET CAP
1.98B
P/E (TTM)
-40.5016
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EIDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EIDX News

  • Insider Weekends: A Look Back At The Hits And Misses Of 2019
  • Seeking Alpha - Article.01/01 10:18
  • Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2019 Update
  • Seeking Alpha - Article.12/18/2019 14:00
  • The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO
  • Benzinga.12/17/2019 12:56
  • The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
  • Benzinga.12/13/2019 13:10

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About EIDX

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.
More

Webull offers Eidos Therapeutics Inc (EIDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.